{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:12:38Z","timestamp":1792721558810,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Amlodipine poisoning is a leading cause of cardiovascular medication\u2010related deaths, commonly managed with high\u2010dose insulin (HDI) therapy. However, HDI is a vasodilator that is counterproductive in managing vasoplegia. We aim to study HDI therapy in patients with hypotension following dihydropyridine calcium channel antagonist (CCA) overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study includes adult patients (\u226515\u2009years) with deliberate dihydropyridine CCA overdose and hypotension (mean arterial pressure &lt;65\u2009mmHg or systolic blood pressure\u2009&lt;90\u2009mmHg) managed by two Poisons Information Centres and three toxicology units in Australia (2020\u20102023). Patients who received HDI\u00a0were compared with those who did not receive HDI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 50 patients (31 female [62%], median age 57\u2009years). Forty\u2010one (82%) coingested a renin\u2013angiotensin system antagonist. Ten (20%) received HDI (median bolus dose of 1\u00a0U\/kg and infusion 1.25\u2009U\/kg\/h, interquartile range: 0.9\u20135.5) and 40 (80%) did not receive HDI therapy. Eight patients in the HDI had echocardiogram, 4 showed left ventricular dysfunction. There were no differences in the 2 groups regarding age, sex, median dose of dihydropyridine and renin\u2013angiotensin system antagonists. Median minimal systolic blood pressure (\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u2009.0007) and mean arterial pressure (\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u2009.0006) were significantly lower prior to starting HDI. There were increased maximal concomitant number of vasopressors\/inotropes used (median difference: 1.5;\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u2009.0002) and at higher doses in the HDI group. Median dose of noradrenaline used was 1.15\u2009\u03bcg\/kg\/min in the HDI group\n                      <jats:italic>vs<\/jats:italic>\n                      . 0.27\u2009\u03bcg\/kg\/min in the non\u2010HDI group (\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u2009.003). One fatality occurred in the non\u2010HDI group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dihydropyridine CCA poisoning with associated hypotension was treated primarily with vasopressor therapy. The inodilator HDI was not commonly used, and it was primarily administered in low doses, utilized mainly in patients with left ventricular dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70081","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T23:38:16Z","timestamp":1745797096000},"page":"2613-2620","source":"Crossref","is-referenced-by-count":8,"title":["Management of hypotension in dihydropyridine calcium channel blocker overdose: The role of high\u2010dose insulin therapy"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0083-282X","authenticated-orcid":false,"given":"Betty S. H.","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Clinical Toxicology Prince of Wales Hospital  Sydney Australia"},{"name":"New South Wales Poisons Information Centre Sydney Children's Hospitals Network  Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Z.","family":"Isoardi","sequence":"additional","affiliation":[{"name":"New South Wales Poisons Information Centre Sydney Children's Hospitals Network  Westmead Australia"},{"name":"Queensland Poisons Information Centre Queensland Children's Hospital  Brisbane Australia"},{"name":"Clinical Toxicology Unit Princess Alexandra Hospital  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-7577","authenticated-orcid":false,"given":"Darren M.","family":"Roberts","sequence":"additional","affiliation":[{"name":"New South Wales Poisons Information Centre Sydney Children's Hospitals Network  Westmead Australia"},{"name":"Edith Collins Centre, Drug Health Services Royal Prince Alfred Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ong Sook","family":"Har","sequence":"additional","affiliation":[{"name":"New South Wales Poisons Information Centre Sydney Children's Hospitals Network  Westmead Australia"},{"name":"Edith Collins Centre, Drug Health Services Royal Prince Alfred Hospital  Sydney Australia"},{"name":"Emergency Dept Hospital Tengku Ampuan Rahimah  Klang Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp20X708053"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"e_1_2_12_4_1","unstructured":"Branch PAaSISPaPP.Pharmaceutical Benefits Scheme (PBS) Expenditure & Prescriptions Report 1 July 2022 to 30 June 20232023."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2020.1834219"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1989785"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2132768"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2268981"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2207733"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000073659"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2020.1826504"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666170622112253"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022\u20103565(24)35330\u20103"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702162"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0267659113498807"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/2.5.355"},{"issue":"9","key":"e_1_2_12_17_1","first-page":"711","article-title":"Poisoning with anti\u2010hypertensive drugs: angiotensin converting enzyme inhibitors","volume":"9","author":"Lip GY","year":"1995","journal-title":"J Hum Hypertens"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2011.02.025"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16258"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002087"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.582471"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2131565"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja17.01063"},{"key":"e_1_2_12_24_1","volume-title":"WHO collaborating Centre for Drug Statistics Methodology. ATC\/DDD index for dihydropyridine derivatives","author":"Health NIoP","year":"2024"},{"key":"e_1_2_12_25_1","volume-title":"ATC\/DDD index for ACE inhibitors, plain","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2024"},{"key":"e_1_2_12_26_1","volume-title":"ATC\/DDD index for angiotensin II receptor blockers","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2024"},{"issue":"2","key":"e_1_2_12_27_1","first-page":"S23","article-title":"The concise guide to PHARMACOLOGY 2023\/24: G protein\u2010coupled receptors","volume":"180","author":"Alexander SPH","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"2","key":"e_1_2_12_28_1","first-page":"S145","article-title":"The concise guide to PHARMACOLOGY 2023\/24: ion channels","volume":"180","author":"Alexander SPH","year":"2023","journal-title":"Br J Pharmacol"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701779695"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012\u2010024\u201009849\u20102"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000001218"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1245"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2110067"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054\u2010018\u20101967\u20103"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15641"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.770152"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2268266"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1967372"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134\u2010019\u201005801\u2010z"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.13836"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2016.1180390"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2013.08.102"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181\u2010017\u20100637\u20101"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38400"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2018.08.017"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181\u2010022\u201000885\u20104"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:33:33Z","timestamp":1775630013000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/bcp.70081"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70081","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]}}}